Makoto Kato

Kusatsu, 5250037, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.

The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.

Journal: Journal of bone and mineral metabolism

Published: May 08, 2020

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.

Journal: Breast cancer (Tokyo, Japan)

Published: October 19, 2019

Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.

Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.

Journal: Journal of bone and mineral metabolism

Published: September 07, 2018

Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.

Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.

Journal: Therapeutics and clinical risk management

Published: July 20, 2018

Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.

Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.

Journal: Anticancer research

Published: May 23, 2018

Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.

Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.

Journal: Breast cancer (Tokyo, Japan)

Published: May 18, 2018

Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.

Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.

Journal: Journal of bone and mineral metabolism

Published: December 21, 2017

Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.

Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.

Journal: Journal of bone and mineral metabolism

Published: August 10, 2017

Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients.

Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients.

Journal: International journal of clinical oncology

Published: March 17, 2015

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.

Journal: International journal of clinical oncology

Published: November 19, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026